Summary
Preliminary investigation in 3 healthy volunteers suggested that intravenous pinacidil in a dose of 0.2 mg/kg had a potent but well-tolerated hypotensive action in the supine position. Facial flushing, uncomfortable chest sensation and distressing postural hypotension occurred at serum concentrations above 300 ng/ml. Pinacidil, 0.2 mg/kg, was given intravenously over 4 min to 15 healthy volunteers in the supine position. Maximum fall in mean arterial pressure (MAP) was 15.7±6.0 mmHg. Maximum rise in heart rate was 23.8±6.6 beats/min. Pinacidil serum distribution half-life (\({\text{T}}_{{\raise0.7ex\hbox{${\text{1}}$} \!\mathord{\left/ {\vphantom {{\text{1}} {{\text{2}}\alpha }}}\right.\kern-\nulldelimiterspace}\!\lower0.7ex\hbox{${{\text{2}}\alpha }$}}}\)) was 13.4±8.5 min and elimination half-life (\({\text{T}}_{{\raise0.7ex\hbox{${\text{1}}$} \!\mathord{\left/ {\vphantom {{\text{1}} {{\text{2}}\beta }}}\right.\kern-\nulldelimiterspace}\!\lower0.7ex\hbox{${{\text{2}}\beta }$}}}\)) was 2.13±0.49 h. The apparent volume of distribution (Vdβ) was 90.3±13.21 and total body clearance was 31.1±9.61/h. Pinacidil was approximately 40% bound to plasma protein over the concentration range 40–400 ng/ml. Urinary excretion of unchanged pinacidil accounted for 5.7 ± 1.3% of the administered dose over 24 hours and urinary excretion of the major metabolite, pinacidil pyridine-N-oxide, was 31.6±9.2% of the administered dose. It was concluded that intravenous pinacidil is a potent vasodilator hypotensive compound, with a duration of action between 1.5 and 2 h.
Similar content being viewed by others
References
Petersen HJ, Nielsen CK, Arrigoni-Martelli E (1978) Synthesis and hypotensive activity of N-alkyl-N″-cyano-N′-pyridylguanidines. J Med Chem 21: 773–781
Arrigoni-Martelli E, Nielsen CK, Olsen UB, Petersen HJ (1980) N″-cyano-N-4-pyridyl-N′-1,2,2,-trimethylpropylguanidine, monohydrate (P1134): a new potent vasodilator. Experientia 36: 445–447
Thoolen MJMC, van Meel JCA, Wilffert B, Timmermans PBMWM, van Zwieten PA (1983) Haemodynamic characterization of pinacidil in rats. Comparison to hydralazine. Pharmacology 27: 245–254
Nielsen CK, Arrigoni-Martelli E (1981) Effect of a new vasodilator, pinacidil (P1134), on potassium, noradrenaline and serotonin induced concentrations in rabbit vascular tissues. Acta Pharmacol Toxicol 49: 427–431
Mikkelsen E, Pedersen OL (1982) Comparison of the effects of a new vasodilator, pinacidil, and nifedipine on isolated blood vessels. Acta Pharmacol Toxicol 51: 407–412
Carlsen JE, Kardel T, Tage H, Mogens T, Trap-Jensen J (1981) Immediate central and peripheral haemodynamic effects of a new vasodilating agent pinacidil (P1134) in hypertensive man. Clin Physiol 1: 357–384
Muiesan G, Fariello R, Muiesan ML (1983) Effects of pinacidil on blood pressure, plasma catecholamines and plasma renin activity in essential hypertensive patients. Clin Pharmacol Ther 33 [2]: p 229 (abstract)
Eilertsen E, Magnussen MP, Petersen HJ, Rastrup-Andersen N, Sorensen H, Arrigoni-Martelli E (1982) Metabolism of the new antihypertensive agent pinacidil in rat, dog and man. Xenobiotica 12 [3]: 187–196
Eilertsen E, Hart JW, Magnussen MP, Sorensen H, Arrigoni-Martelli E (1982) Pharmacokinetics and distribution of the new antihypertensive agent, pinacidil, in rat, dog and man. Xenobiotica 12 [3]: 177–185
Diem K (1962) Scientific tables. Documenta Geigy, New York, p 314
Riegelman S, Loo JCK, Rowland M (1968) Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment. J Pharm Sci 57: 117–123
Shepherd AMM, McNay JL, Ludden TM, Lin MS, Musgrave GE (1981) Plasma concentration and acetylator status phenotype determine response to oral hydralazine. Hypertension 3: 580–585
Shepherd AMM, Musgrave GE, Badke FR, Walsh R (1980) Tachycardia associated with hydralazine pyruvic acid hydrazone, the major plasma metabolite of hydralazine. Fed Proc 39: p 1190 (abstract)
Bateman DN, Hobbs, DC, Twomey TM, Stevens EA, Rawlins MD (1979) Prazosin pharmacokinetics and concentration effect. Eur J Clin Pharmacol 16: 177–181
Elliott HL, McLean K, Sumner DJ, Meredith PA, Reid JL (1981) Immediate cardiovascular responses to oral prazosineffects of concurrent β-blockers. Clin Pharmacol Ther 29: 303–309
Elliott HL, Meredith PA, Sumner DJ, McLean K, Reid JL (1982) A pharmacodynamic and pharmacokinetic assessment of a new α-adrenoceptor antagonist, doxazosin (UK 33274) in normotensive subjects. Br J Clin Pharmacol 13: 699–703
Kardel T, Hilden T, Carlsen J, Trap-Jensen J (1981) N″-cyano-N-4-pyridyl-N′-1,2,2-trimethylpropylguanidine, a new vasodilating agent: acute effect on blood pressure and pharmacokinetics in hypertensive patients. J Cardiovasc Pharmacol 3: 1002–1007
Reece AP, Cozamanis I, Zacest R (1980) Kinetics of hydralazine and its main metabolites in slow and fast acetylators. Clin Pharmacol Ther 28: 769–778
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ward, J.W., McBurney, A., Farrow, P.R. et al. Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator. Eur J Clin Pharmacol 26, 603–608 (1984). https://doi.org/10.1007/BF00543493
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00543493